I think is the thing that we’re going to be working together to figure out. We’ve got some hypothesis about what might be needed. But the proof is ultimately in the assays that you do preclinically to show that you can get a good therapeutic index and deliver enough degrader at the effect that you want in the tumors. So this is the first of the programs. There certainly is the potential for that particular small molecule degrader to go into different cancers, and that would require a different antibody. So that’s on the table. The collaboration has the potential also to go into other antibody drug conjugates where the concept is to use small molecules, not just as sort of a blend instrument poison, like many cytotoxics, but to be much more targeted at precision pathways.
And that could be degraders that could also be other molecular entities that the team at Prelude is able to bring forward. So we’re at the very beginning of this, one of the big values for both teams is we get into a new space and we’ll be learning and working together. And we’re excited about the chance to do something that makes a difference for patients. And hopefully – and I’ve got confidence this will be a successful one, and we’ll be able to update you as it progresses.
Operator: The next question will be from the line of Puneet Souda with Leerink Partners.
Puneet Souda: A couple of questions here. Just maybe first a simple one for 575 and 675. When do we see the early data here for both of them? Maybe just let’s start there.
Carl Hansen: Yes. So for 575, I expect that we will provide some data — some preclinical data ahead of IND filing. I’m not sure exactly on the time line right now, but we’ll update you with that as it comes along. For 635, as mentioned, for strategic reasons, we do not think it would be wiser in the interest of the business to disclose the target or even the indication. And so that one, we’re going to keep close to our chest until it gets to IND.
Andrew Booth : And Puneet — sorry, Carl mentioned in his prepared remarks, but the INDs would be in 2025.
Puneet Souda: Yes, yes. So that’s — that’s kind of related to my sort of second question is, Andrew, can you just remind us what the level of investment or CapEx that you have towards the GMP facility, sort of the outlay that you have for 2024 here before the opening of that facility. And obviously, if you have a drug that’s going to be filed into sort of IND, this is — there’s a lot of early stage work that needs to be done. So can you maybe talk about sort of how are you going to set the priority for or who’s going to set the priority for what is going to be manufactured in that GMP facility. And then maybe just — if you look at the overall capacity in the CDMO landscape today, there’s a bit of an overcapacity situation. Does that impact you at all as you think about how to fill that facility in ’25?
Carl Hansen: Carl, here. Maybe I’ll start, and Andrew can fill in if I miss something. So first of all, for the first two programs, ABCL575 and ABCL635, we will be having these manufactured by a third-party since our manufacturing facility is not up and running. And for both programs, we believe it’s imperative these move forward as quickly as possible. The manufacturing capability should come online in 2025. That’s the same year that the INDs we expect to be filed for 635 and 575. The first program through the GMP facility are very likely to be AbCellera internal programs. We also expect that we’ll be doing programs that come from strategic partnerships, obviously, with firms that do not have large manufacturing capabilities internally.
